Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Tonghua Dongbao Doses First Patient in China Phase III Trial of Ultra-Rapid Insulin

publication date: May 10, 2022

Tonghua Dongbao Pharma has dosed the first person in a China Phase III trial of an Ultra-Rapid insulin developed by Adocia of Lyon, France. The trial will enroll 1300 people with type 1 and type 2 diabetes in 100 China sites. As part of a two-drug deal,, Tonghua Dongbao in-licensed China and South-East Asia rights to BioChaperone® Lispro from Adocia for $10 million upfront and $35 million in milestones, plus royalties. The second Adocia diabetes therapy in the deal is a fixed-ratio glargine and lispro combination. More details....

Stock Symbols: (SHA: 600867) (Paris: ADOC)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here